We are live on ! Find out more
ACET icon

Adicet Bio

48 hedge funds and large institutions have $190M invested in Adicet Bio in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more capital invested

Capital invested by funds: $128M → $190M (+$61.8M)

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

1.13% less ownership

Funds ownership: 53.14% → 52.02% (-1.1%)

2% less funds holding

Funds holding: 49 → 48 (-1)

Holders
48
Holders Change
-1
Holders Change %
-2.04%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
17
Reduced
13
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ACET Hedge Fund Activity: Q2 2019 in Review

48 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2019, worth a combined $190M — up 48% from $128M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ACET positions and 9 closed out — a net gain of 1 holder — while 17 added to existing stakes and 13 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $35M. The largest seller was Deltec Asset Management, cutting an estimated $2.86M.

  • 48 institutional investors held Adicet Bio (ACET) as of Q2 2019, down from 49 in Q1 2019.
  • Funds reported $190M of Adicet Bio stock for Q2 2019, up 48% quarter-over-quarter.
  • 10 funds opened new Adicet Bio positions in Q2 2019 and 9 closed out, a net change of +1 holder.
  • The largest Adicet Bio buyer in Q2 2019 was Invesco, an estimated $35M added.
  • The largest Adicet Bio seller in Q2 2019 was Deltec Asset Management, an estimated $2.86M sold.

Based on aggregated 13F filings for Q2 2019.